Nolvadex (Tamoxifen Citrate)

Tamoxifen Citrate, the active ingredient in Nolvadex, is a selective estrogen receptor modulator presented as an oral formulation for oral use. It is employed to treat estrogen receptor‑positive breast cancer and to prevent gynecomastia in men receiving certain hormonal therapies.

GNH USA supplies Nolvadex as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with robust quality assurance and regulatory compliance. Our distribution network ensures timely delivery and adherence to local import requirements across Europe, Asia, Africa and the Americas.

Nolvadex (tamoxifen citrate) is used in hormone‑responsive cancers and related conditions, acting on estrogen pathways.

Estrogen receptor‑positive breast cancer (adjuvant and metastatic): reduces tumor growth and lowers risk of disease recurrence. Prevention of breast cancer recurrence: administered after primary therapy to maintain remission. Gynecomastia prophylaxis in men receiving certain hormonal therapies: helps prevent development of breast tissue enlargement.

Tamoxifen citrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Nausea: mild to moderate stomach upset. - Fatigue: generalized tiredness. - Menstrual irregularities: changes in cycle length or flow.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Endometrial cancer: abnormal uterine bleeding or malignancy. - Liver function abnormalities: elevated enzymes or hepatitis. - Visual disturbances: blurred vision or retinal changes.

When prescribing tamoxifen, clinicians should observe several safety measures.

- Liver monitoring: assess hepatic function before and during therapy. - Thromboembolic risk assessment: evaluate history of clotting disorders. - Uterine evaluation: perform baseline gynecologic exam for endometrial risk. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Concomitant estrogen avoidance: do not combine with estrogen‑containing products. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Tamoxifen interacts with several medicines that may alter its efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing hormonal therapies: may diminish tamoxifen efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma levels and toxicity. - Warfarin: tamoxifen may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): reduce conversion to active metabolite, lowering effectiveness. - St. John’s wort: induces CYP3A4, potentially decreasing tamoxifen exposure.